SARS vaccine development.
Identifieur interne : 002641 ( PubMed/Curation ); précédent : 002640; suivant : 002642SARS vaccine development.
Auteurs : Shibo Jiang [États-Unis] ; Yuxian He ; Shuwen LiuSource :
- Emerging infectious diseases [ 1080-6040 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical : Epitopes, Spike Glycoprotein, Coronavirus, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Humans.
Abstract
Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.
DOI: 10.3201/1107.050219
PubMed: 16022774
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002641
Links to Exploration step
pubmed:16022774Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS vaccine development.</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="1"><nlm:affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York 10021</wicri:regionArea></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16022774</idno><idno type="pmid">16022774</idno><idno type="doi">10.3201/1107.050219</idno><idno type="wicri:Area/PubMed/Corpus">002641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002641</idno><idno type="wicri:Area/PubMed/Curation">002641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002641</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS vaccine development.</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="1"><nlm:affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York 10021</wicri:regionArea></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name></author></analytic><series><title level="j">Emerging infectious diseases</title><idno type="ISSN">1080-6040</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Epitopes</term><term>Humans</term><term>Membrane Glycoproteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS (immunologie)</term><term>Épitopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Epitopes</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Épitopes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16022774</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Emerging infectious diseases</Title><ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>SARS vaccine development.</ArticleTitle><Pagination><MedlinePgn>1016-20</MedlinePgn></Pagination><Abstract><AbstractText>Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Infect Dis</MedlineTA><NlmUniqueID>9508155</NlmUniqueID><ISSNLinking>1080-6040</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>39</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId><ArticleId IdType="pmc">PMC3371787</ArticleId><ArticleId IdType="doi">10.3201/1107.050219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3289-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15731223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):134-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15749129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 3;361(9368):1519-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12737864</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2003 Dec 12;115(6):652-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14675530</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Jan 30;314(1):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14715271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jan 10;363(9403):99-104</Citation><ArticleIdList><ArticleId IdType="pubmed">14726162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Genomics. 2004 Jul 8;18(2):245-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15161967</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15356154</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1991 Dec 1;174(6):1557-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1836013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1993 Apr;74 ( Pt 4):745-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7682252</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Nov 19;279(47):49414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15345712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(3):1906-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15650214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002641 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002641 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16022774
|texte= SARS vaccine development.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16022774" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |